** Analysts at Jefferies downgrade rating to "hold" from "buy" on New Zealand's Fisher & Paykel Healthcare FPH.NZ
** Jefferies says it is interested in knowing the impacts FPH has faced from U.S. tariffs to date, when it reports FY25 results on May 28; to keep a close eye on co's mitigation strategies
** However, brokerage keeps PT unchanged at NZ$39.40 per share
** We understand the primary impact on FPH imports is currently a 10% tariff on New Zealand products — brokerage
** One of 12 analysts rate the stock "buy" or higher, nine "hold" and two "sell" or lower; their median PT is NZ$35.81, according to data compiled by LSEG
** Stock has fallen 4.3% this year, as of last close
(Reporting by Roshan Thomas in Bengaluru)
((Roshan.Thomas@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。